Novo Nordisk has hit a major setback in chronic kidney disease drug development after a phase 3 trial of ziltivekimab failed. The result puts pressure on the company’s broader CKD strategy and raises fresh doubts about the path forward for the program.
Based on the limited details available, the failed late-stage study appears to be a significant blow because phase 3 trials are typically designed to support regulatory filings and commercial plans. When a study at that stage misses expectations, companies often have to reassess both the medicine and the wider development plan around it.
The headline suggests Novo Nordisk is now looking to Artemis and Hermes to help salvage the CKD program. Those names appear to refer to other parts of the development effort, making them especially important after the ziltivekimab phase 3 disappointment. Their progress could shape whether Novo Nordisk can still build a meaningful position in kidney disease treatment.
For Novo Nordisk, the failed ziltivekimab phase 3 trial is more than a single-study miss. It creates uncertainty around a key kidney disease program and shifts attention to whatever evidence Artemis and Hermes may still deliver.
